Form 4: Tharimmune Inc. Executive Acquires Shares in Open Market Transaction

A Tharimmune Inc. executive, Sireesh Appajosyula, has acquired 5,000 shares of common stock at a price of $2.0192 per share.

Summary

• Sireesh Appajosyula, Chief Operating Officer of Tharimmune Inc., purchased 5,000 shares of the company's common stock on November 13, 2024.
• The shares were acquired at a price of $2.0192 each.
• Following the transaction, Mr. Appajosyula directly owns 10,758 shares of Tharimmune Inc. common stock.
• He also indirectly owns 2,593 shares through Highpoint Pharmaceuticals, LLC and 21 shares through Channel BioConsulting LLC, where he is the managing member.

Sentiment

Score: 6

Explanation: The document reflects a routine transaction by an executive, which is neither overly positive nor negative. It indicates confidence but is not a major event.

Positives

• The purchase of shares by a company executive can be seen as a positive sign of confidence in the company's future prospects.

Industry Context

This is a standard SEC Form 4 filing, which is common when company insiders trade shares. It provides transparency into the transactions of company executives.

Comparison to Industry Standards

• Form 4 filings are a standard practice for publicly traded companies in the United States, ensuring transparency of insider transactions.
• The transaction is typical of open market purchases by executives and is not unusual in the biotech industry.

Stakeholder Impact

• The share purchase may have a slightly positive impact on shareholder sentiment, as it indicates confidence from a company executive.

Key Dates

Keywords

Tharimmune, Share Acquisition, Insider Trading, Form 4, Sireesh Appajosyula, Chief Operating Officer, Stock Purchase